ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,281 to 3,300 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Nonhydrolysed Infant Formula vs Hydrolysed Infant Formula: Number of Participants With Type 1 Diabetes Mellitus82 of 1,078

91 of 1,081

-0.8 points

-3.1 to 1.5

2,159NCT00179777

TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk

Nonhydrolysed Infant Formula vs Hydrolysed Infant Formula: deaths from any cause5 of 1,078

5 of 1,081

0.0 points

-0.7 to 0.7

2,159NCT00179777

TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk

Nonhydrolysed Infant Formula vs Hydrolysed Infant Formula: serious adverse events379 of 1,078

377 of 1,081

0.3 points

-3.7 to 4.3

2,159NCT00179777

TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk

With Complications vs Without Complications: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Complications129 of 777

134 of 1,380

6.9 points

3.9 to 10.0

2,157NCT00605865

Drug Use Investigation of Jzoloft.

With Concomitant Drug vs Without Concomitant Drug: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Concomitant Drug238 of 1,864

25 of 293

4.2 points

0.2 to 7.4

2,157NCT00605865

Drug Use Investigation of Jzoloft.

With Past Medical History of Other Illness vs Without Past Medical History of Other Illness: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Past Medical History of Other Illness57 of 349

206 of 1,808

4.9 points

1.1 to 9.4

2,157NCT00605865

Drug Use Investigation of Jzoloft.

With Renal Dysfunction vs Without Renal Dysfunction: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Renal Dysfunction7 of 24

256 of 2,133

17.2 points

2.8 to 37.2

2,157NCT00605865

Drug Use Investigation of Jzoloft.

15 Years and Higher vs Under 15 Years: Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: 15 Years and Higher of Age or Not261 of 2,153

2 of 4

-37.9 points

-72.9 to -2.9

2,157NCT00605865

Drug Use Investigation of Jzoloft.

120 mg Elafibranor vs Placebo: deaths from any cause6 of 1,437

3 of 720

0.0 points

-0.8 to 0.6

2,157NCT02704403

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

Seqirus Quadrivalent Influenza Vaccine vs Comparator Quadrivalent Influenza Vaccine: Safety Endpoint: The Frequency of Cellulitis-like Reaction.1 of 1,621

0 of 535

0.1 points

-0.7 to 0.3

2,156NCT02545543

A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age

MVA-NP+M1 Group vs Saline Placebo Group: deaths from any cause0 of 1,077

1 of 1,075

-0.1 points

-0.5 to 0.3

2,152NCT03880474

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

MVA-NP+M1 Group vs Saline Placebo Group: serious adverse events18 of 1,077

22 of 1,075

-0.4 points

-1.6 to 0.8

2,152NCT03880474

Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults

Couples-based Services vs Standard of Care: deaths from any cause23 of 1,047

25 of 1,104

-0.1 points

-1.4 to 1.2

2,151NCT03149237

Partners-based HIV Treatment for Couples Attending Antenatal Care

120 mg Elafibranor vs Placebo: serious adverse events190 of 1,433

95 of 717

0.0 points

-3.1 to 3.0

2,150NCT02704403

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

Edoxaban vs Warfarin: deaths from any cause1 of 1,067

5 of 1,082

-0.4 points

-1.0 to 0.1

2,149NCT02072434

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

Edoxaban vs Warfarin: serious adverse events85 of 1,067

83 of 1,082

0.3 points

-2.0 to 2.6

2,149NCT02072434

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

CKD Enhanced Clinical Decision Support (CKD-CDS Intervention) vs Usual Care: Number of Patients With Orders for Angiotensin-converting Enzyme Inhibitors (ACEI) or Angiotension II Reception Blockers (ARB)151 of 952

192 of 1,192

-0.2 points

-3.3 to 2.9

2,144NCT03890588

Chronic Kidney Disease Clinical Decision Support

Pre-Intervention: Patients Diagnosed With Conditions of Interest During Study Period vs Post-Intervention: Patients Diagnosed With Conditions of Interest During Study Period: Guideline-concordant Decision to Not Prescribe Antibiotics for Pediatric Acute Otitis Media284 of 1,155

292 of 983

-5.1 points

-8.9 to -1.3

2,138NCT06027593

Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions

DTaP-IPV-Hep B-PRP~T vs Tritanrix-Hep B/Hib™ + OPV: serious adverse events91 of 1,423

46 of 710

-0.1 points

-2.4 to 2.0

2,133NCT00313911

Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.

Group 1: DTaP-Hep B-PRP~T + OPV vs Group 2: Tritanrix-Hep B/ Hib™ + OPV: serious adverse events31 of 1,425

12 of 708

0.5 points

-0.9 to 1.6

2,133NCT00348881

Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy Infants

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=165"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=165

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00179777-6cda80a4",
        "title": "Nonhydrolysed Infant Formula vs Hydrolysed Infant Formula: Number of Participants With Type 1 Diabetes Mellitus",
        "summary": "82 of 1078 against 91 of 1081; risk difference -0.8 points, 95% interval -3.1 to 1.5; NCT00179777, TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk",
        "record": "/library/comparisons/NCT00179777-6cda80a4",
        "nct_id": "NCT00179777",
        "kind": "outcome",
        "participants": 2159,
        "risk_difference": {
          "value": -0.008114523246015262,
          "lower": -0.03119033688895616,
          "upper": 0.014914713921671176
        },
        "group_1": "82 of 1,078",
        "group_2": "91 of 1,081",
        "difference": "-0.8 points",
        "interval": "-3.1 to 1.5",
        "trial_title": "TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk"
      },
      {
        "id": "NCT00179777-deaths",
        "title": "Nonhydrolysed Infant Formula vs Hydrolysed Infant Formula: deaths from any cause",
        "summary": "5 of 1078 against 5 of 1081; risk difference 0.0 points, 95% interval -0.7 to 0.7; NCT00179777, TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk",
        "record": "/library/comparisons/NCT00179777-deaths",
        "nct_id": "NCT00179777",
        "kind": "deaths",
        "participants": 2159,
        "risk_difference": {
          "value": 0.00001287202291563351,
          "lower": -0.006691794455961104,
          "upper": 0.006730246937222214
        },
        "group_1": "5 of 1,078",
        "group_2": "5 of 1,081",
        "difference": "0.0 points",
        "interval": "-0.7 to 0.7",
        "trial_title": "TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=166",
  "request_id": "SCyTA_CQu5XoPM76"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?